Cochrane · systematic review · CD012619

Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis

Carroll, W, Green, J, Gilchrist, FJ · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library

Cystic Fibrosis and Genetic Disorders2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Cisapride compared to placebo for preventing DIOS in cystic fibrosis

Population: people with cystic fibrosis
CD012619.PUB3 (current) · 7 questions
OutcomeEffectEvidenceStatus / GRADE
Radiological diagnosis of DIOS (physician‐measured radiological scores)
Cisapride vs placebo
no estimate extracted1 study · 17 participantsVery low
Downgraded: risk of bias, imprecision
Adverse effects (participant interviews)
Cisapride vs placebo
no estimate extracted1 study · 17 participantsVery low
Downgraded: risk of bias, imprecision
Total gastrointestinal symptom scores (participant‐reported symptom scores from 20 to 100)
Cisapride vs placebo
no estimate extracted1 study · 17 participantsVery low
Downgraded: risk of bias, imprecision
Hospitalisation for any cause
Cisapride vs placebo
no estimate extractedNRNo studies
Hospitalisation for DIOS
Cisapride vs placebo
no estimate extractedNRNo studies
Quality of life
Cisapride vs placebo
no estimate extractedNRNo studies
Tolerability
Cisapride vs placebo
no estimate extractedNRNo studies

Cisapride compared to placebo for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis

Population: preventing DIOS in cystic fibrosis
CD012619.PUB2 · 7 questions
OutcomeEffectEvidenceStatus / GRADE
Radiological diagnosis of DIOS (physician‐measured radiological scores)
Cisapride vs placebo
no estimate extracted1 study · 17 participantsVery low
Downgraded: risk of bias, imprecision
Adverse effects (participant interviews)
Cisapride vs placebo
no estimate extracted1 study · 17 participantsVery low
Downgraded: risk of bias, imprecision
Total gastrointestinal symptom scores (participant‐reported symptom scores from 20 to 100)
Cisapride vs placebo
no estimate extracted1 study · 17 participantsVery low
Downgraded: risk of bias, imprecision
Hospitalisation for any cause
Cisapride vs placebo
no estimate extractedNRNo studies
Hospitalisation for DIOS
Cisapride vs placebo
no estimate extractedNRNo studies
Quality of life
Cisapride vs placebo
no estimate extractedNRNo studies
Tolerability
Cisapride vs placebo
no estimate extractedNRNo studies